KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Raw Materials (2016 - 2021)

Historic Raw Materials for Biomarin Pharmaceutical (BMRN) over the last 12 years, with Q3 2021 value amounting to $75.3 million.

  • Biomarin Pharmaceutical's Raw Materials rose 199.17% to $75.3 million in Q3 2021 from the same period last year, while for Sep 2021 it was $75.3 million, marking a year-over-year increase of 199.17%. This contributed to the annual value of $76.7 million for FY2020, which is 299.7% up from last year.
  • Biomarin Pharmaceutical's Raw Materials amounted to $75.3 million in Q3 2021, which was up 199.17% from $83.7 million recorded in Q2 2021.
  • In the past 5 years, Biomarin Pharmaceutical's Raw Materials registered a high of $83.7 million during Q2 2021, and its lowest value of $46.5 million during Q2 2018.
  • Its 5-year average for Raw Materials is $65.3 million, with a median of $68.4 million in 2019.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Raw Materials skyrocketed by 4960.0% in 2018 and then plummeted by 442.18% in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's Raw Materials (Quarter) stood at $49.9 million in 2017, then surged by 49.6% to $74.6 million in 2018, then dropped by 0.23% to $74.4 million in 2019, then grew by 3.0% to $76.7 million in 2020, then fell by 1.75% to $75.3 million in 2021.
  • Its Raw Materials was $75.3 million in Q3 2021, compared to $83.7 million in Q2 2021 and $78.6 million in Q1 2021.